Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Form 8-K on January 8, 2026, reporting the entry into a Material Definitive Agreement. The Company is a Delaware corporation headquartered in Seattle, Washington, with common stock trading on The Nasdaq Stock Market LLC.
Key Financial Metrics and Agreement Terms
- Commitment Amount: Up to $60.0 million in common stock available for issuance over 36 months.
- Purchase Price: 96% of the lowest daily Volume Weighted Average Price (VWAP) during a three consecutive trading day period.
- Fees: A one-time structuring fee of $25,000 was paid. A commitment fee of 2.00% of the Commitment Amount ($1.2 million total) is payable in five equal quarterly installments.
- Issuance Cap: Limited to 199,466 shares (19.99% of outstanding shares) unless shareholder approval is obtained or the average sale price exceeds $8.753 per share.
- Beneficial Ownership Limit: Yorkville's obligation is capped if its beneficial ownership exceeds 9.99% of outstanding voting power.
Material Changes
This filing represents a new financing arrangement rather than a change in historical financial performance. The Company has secured a potential source of liquidity through the Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. ("Yorkville"). No revenue, profit, or cash flow figures for the current or prior periods are provided in this specific filing.
Guidance, Outlook, and Risks
- Outlook: The agreement provides the Company with the option to raise capital as needed over the next three years, subject to market conditions and the 9.99% beneficial ownership limit.
- Conditions: Yorkville's obligation to purchase shares is contingent upon the filing and effectiveness of a registration statement with the SEC.
- Risks: The Company may be unable to issue shares if the price falls below the minimum acceptable price specified by the Company or if the issuance would breach Nasdaq Rules regarding the 19.99% exchange cap.
- Unusual Items: The Company has the option to satisfy the fourth and fifth commitment fee installments by issuing shares equivalent to the fee amount rather than paying cash.
Investor Verification Checklist
- Verify the effectiveness of the Registration Statement required for the sale of Advance Shares.
- Monitor the Company's stock price relative to the $8.753 threshold to determine if the 19.99% issuance cap can be exceeded without shareholder approval.
- Review the Company's cash position to assess the impact of the quarterly commitment fee payments.
- Confirm the Company's current outstanding share count to calculate the precise number of shares available under the 19.99% cap.